This segment focuses on the research, development, and clinical evaluation of oncolytic viral immunotherapies for various cancers. Candel Therapeutics utilizes its Gene Mediated Cytotoxic Immunotherapy (GMCI) platform, which includes the use of modified adenoviruses and herpes simplex viruses (HSV) to target and kill cancer cells while stimulating an immune response. Research and development activities include preclinical studies, clinical trials, and manufacturing process development. The primary therapeutic areas are prostate cancer, pancreatic cancer, and recurrent high-grade glioma. The goal is to improve patient outcomes by eradicating residual tumor cells and preventing recurrence or metastasis. Candel's market positioning is based on its innovative approach to cancer treatment, and its competitive advantage lies in its proprietary technology and clinical pipeline. Future opportunities include expanding the pipeline to other cancer types and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA and EMA approval processes. Partnerships and collaborations are crucial for clinical trial execution and commercialization, as seen with collaborations with the University of Pennsylvania and IDEA Pharma.